Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients (2 to 11 years) with atopic dermatitis.

Dr. Chovatiya discusses a recent poster presented at the 2025 Revolutionizing Atopic Dermatitis Conference which evaluated the effectiveness of upadacitinib in achieving long-term maintenance of...
PLAY